Skip to main content
. 2018 Feb 2;36(5):591–601. doi: 10.1007/s40273-017-0604-3

Fig. 2.

Fig. 2

Cost-effectiveness acceptability frontier for genotype 1. PAR paritaprevir, RIT ritonavir, OMB ombitasvir, DAS dasabuvir, PEG peginterferon-α-2a, RBV ribavirin, QALY quality-adjusted life-year